Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy
Ofrat Beyar‐Katz(Rambam Health Care Campus), Yuval Shaked(Technion – Israel Institute of Technology), Noa Lavi(Rambam Health Care Campus), Noga Barak(Technion – Israel Institute of Technology), Marina Bersudsky(Ben-Gurion University of the Negev), Ksenia Magidey(Rappaport Family Institute for Research in the Medical Sciences), Elena Voronov(Ben-Gurion University of the Negev), Shimrit Avraham(Technion – Israel Institute of Technology), Michal Hayun(Rambam Health Care Campus), Ron N. Apte(Ben-Gurion University of the Negev), Yaël C. Cohen(Tel Aviv University), Anat Reiner‐Benaim(Rambam Health Care Campus), Irit Avivi(Tel Aviv Sourasky Medical Center), Michael Timaner(Technion – Israel Institute of Technology)
Cited by 34
Related Papers
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
IL-1α and IL-1β Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation
|The Journal of Immunology|2011|519
Classification of current anticancer immunotherapies
|Oncotarget|2014|469
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
|Blood Advances|2021|170
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
|Transplantation and Cellular Therapy|2021|164